Date of Patent: Jun. 06, 2017 Applicant:
Dupont Tate & Lyle Bio Products Company, Llc , Wilmington, DE (US) ;
Inventors:
Robert Miller , Wilmington, DE (US) ;
Joseph Desalvo , Lafayette Hill, PA (US) ;
Gyorgyi Fenyvesi , Wilmington, DE (US) ;
Melissa Joerger , Newark, DE (US) ;
Raja Hari Poladi , Bear, DE (US) ;
Ann Wehner , Hockessin, DE (US) ;
Int. Cl.
CPC ...
A61K 31/22 (2006.01) ; A61K 31/23 (2006.01) ; A61K 31/045 (2006.01) ; A61K 35/12 (2015.01) ; A61K 35/20 (2006.01) ; A61K 36/00 (2006.01) ; A61K 8/34 (2006.01) ; A21D 2/14 (2006.01) ; A23B 7/154 (2006.01) ; A23L 2/52 (2006.01) ; A23L 3/3463 (2006.01) ; A61K 8/02 (2006.01) ; A61K 8/37 (2006.01) ; A61K 47/14 (2017.01) ; A61K 47/44 (2017.01) ; A61Q 1/02 (2006.01) ; A61Q 1/08 (2006.01) ; A61Q 1/10 (2006.01) ; A61Q 5/02 (2006.01) ; A61Q 5/12 (2006.01) ; A61Q 11/00 (2006.01) ; A61Q 15/00 (2006.01) ; A61Q 17/04 (2006.01) ; A61Q 19/00 (2006.01) ; A61Q 19/10 (2006.01) ; B01D 11/02 (2006.01) ; C07C 67/08 (2006.01) ; C07C 69/16 (2006.01) ; C07C 69/28 (2006.01) ; C07C 69/44 (2006.01) ; C07C 69/58 (2006.01) ; C07C 69/60 (2006.01) ; C07C 69/78 (2006.01) ; C08K 5/103 (2006.01) ; C09D 7/12 (2006.01) ; C09D 11/03 (2014.01) ; C09G 1/08 (2006.01) ; C09K 3/18 (2006.01) ; C09K 5/10 (2006.01) ; C09K 5/20 (2006.01) ; C11C 3/00 (2006.01) ; C11D 1/66 (2006.01) ; C11D 3/20 (2006.01) ; C11D 3/34 (2006.01) ; C11D 7/26 (2006.01) ; C11D 7/50 (2006.01) ; C12P 7/18 (2006.01) ; C12P 7/42 (2006.01) ; C12P 7/62 (2006.01) ; A61K 8/92 (2006.01) ; C11D 3/386 (2006.01) ; A01N 25/02 (2006.01) ; A61K 36/02 (2006.01) ; A61K 36/185 (2006.01) ; A61K 36/28 (2006.01) ; A61K 36/355 (2006.01) ; A61K 36/61 (2006.01) ; A61K 36/738 (2006.01) ; A61K 47/10 (2017.01) ; A61Q 9/04 (2006.01) ; A61Q 13/00 (2006.01) ; A23K 20/105 (2016.01) ; A23L 29/00 (2016.01) ; A23L 29/10 (2016.01) ; A23L 33/10 (2016.01) ; A23L 33/12 (2016.01) ; A61K 9/00 (2006.01) ; A61K 9/06 (2006.01) ; A61K 9/28 (2006.01) ; A61Q 1/14 (2006.01) ; A61Q 5/00 (2006.01) ; A61Q 5/10 (2006.01) ; A61Q 9/02 (2006.01) ; A61Q 17/00 (2006.01) ; A61Q 19/04 (2006.01) ;
U.S. Cl.
CPC ...
A61K 8/345 (2013.01) ; A01N 25/02 (2013.01) ; A21D 2/14 (2013.01) ; A23B 7/154 (2013.01) ; A23K 20/105 (2016.05) ; A23L 2/52 (2013.01) ; A23L 3/3463 (2013.01) ; A23L 29/035 (2016.08) ; A23L 29/04 (2016.08) ; A23L 29/10 (2016.08) ; A23L 33/10 (2016.08) ; A23L 33/12 (2016.08) ; A61K 8/0208 (2013.01) ; A61K 8/375 (2013.01) ; A61K 8/92 (2013.01) ; A61K 31/22 (2013.01) ; A61K 36/02 (2013.01) ; A61K 36/185 (2013.01) ; A61K 36/28 (2013.01) ; A61K 36/355 (2013.01) ; A61K 36/61 (2013.01) ; A61K 36/738 (2013.01) ; A61K 47/10 (2013.01) ; A61K 47/14 (2013.01) ; A61K 47/44 (2013.01) ; A61Q 1/02 (2013.01) ; A61Q 1/08 (2013.01) ; A61Q 1/10 (2013.01) ; A61Q 5/02 (2013.01) ; A61Q 5/12 (2013.01) ; A61Q 9/04 (2013.01) ; A61Q 11/00 (2013.01) ; A61Q 13/00 (2013.01) ; A61Q 15/00 (2013.01) ; A61Q 17/005 (2013.01) ; A61Q 17/04 (2013.01) ; A61Q 19/00 (2013.01) ; A61Q 19/002 (2013.01) ; A61Q 19/007 (2013.01) ; A61Q 19/10 (2013.01) ; B01D 11/0288 (2013.01) ; C07C 67/08 (2013.01) ; C07C 69/16 (2013.01) ; C07C 69/28 (2013.01) ; C07C 69/44 (2013.01) ; C07C 69/58 (2013.01) ; C07C 69/60 (2013.01) ; C07C 69/78 (2013.01) ; C08K 5/103 (2013.01) ; C09D 7/1233 (2013.01) ; C09D 11/03 (2013.01) ; C09G 1/08 (2013.01) ; C09K 3/18 (2013.01) ; C09K 5/10 (2013.01) ; C09K 5/20 (2013.01) ; C11C 3/003 (2013.01) ; C11D 1/667 (2013.01) ; C11D 3/2003 (2013.01) ; C11D 3/2044 (2013.01) ; C11D 3/2068 (2013.01) ; C11D 3/2093 (2013.01) ; C11D 3/3418 (2013.01) ; C11D 3/38663 (2013.01) ; C11D 7/266 (2013.01) ; C11D 7/5022 (2013.01) ; C12P 7/18 (2013.01) ; C12P 7/42 (2013.01) ; C12P 7/62 (2013.01) ; A61K 9/0019 (2013.01) ; A61K 9/06 (2013.01) ; A61K 9/282 (2013.01) ; A61K 2800/75 (2013.01) ; A61Q 1/14 (2013.01) ; A61Q 5/00 (2013.01) ; A61Q 5/10 (2013.01) ; A61Q 9/02 (2013.01) ; A61Q 17/00 (2013.01) ; A61Q 19/005 (2013.01) ; A61Q 19/04 (2013.01) ; C10M 2207/283 (2013.01) ;
Abstract Biodegradable pharmaceutical compositions comprising 1,3-propanediol and its esters are provided. The 1,3-propanediol and its esters in the pharmaceutical composition are biologically derived, and as such, the pharmaceutical compositions exhibit a low anthropogenic COemission profile.
Find Patent Forward Citations
Click to load US Patent References
Cite this Patent (APA, Harvard, BibTeX)
Miller, Robert. (2017). Pharmaceutical compositions comprising renewably-based biodegradable 1,3-propanediol (U.S. Patent No. 9668951). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9668951
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile